Wednesday, October 24, 2018 MA.39 - Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer The randomization of the first MA.39 patient has been completed by the Juravinski Cancer Centre at Hamilton Health Sciences on October 16, 2018 - Congratulations! This site is lead by the Study Chair Tim Whelan and has four additional patients registered. There are 34 sites active for the study, 8 of them are in Canada with more than 15 Canadian sites working toward activation at this time. CCTG is interested in activating additional sites delivering radiotherapy to breast cancer patients as soon as possible. Please contact us if you have questions or issues that we could help with to expedite your site activation. For more information on the study visit the MA.39 trail page or contact the CCTG study coordinator Alexander Montenegro-Suris. This trial is under specific accrual rules that need to be met. Site activation processes and patient screening need to be optimized in order to be able to complete the study. Let us know if you find specific selection or protocol requirements that are limiting patients to be eligible for the study. Please note that the trial is looking for more sites to activate, please contact CCTG if your site is interested: Alexander Montenegro-Suris. Canadian sites currently active for this trial: Hopital de la Cite-de-la-Sante, Laval, QC Centre hospitalier universitaire de Sherbrooke, QC CHUQ-Pavillon Hotel-Dieu de Quebec, QC Ottawa Hospital Research Institute, ON Juravinski Cancer Centre at Hamilton Health Sciences, ON London Regional Cancer Program, ON Allan Blair Cancer Centre, SK BCCA - Vancouver Island Cancer Centre, Victoria, BC
